NCT05312320

Brief Summary

The study is completely digital. Men and women who recently had an MI will be invited through a written brochure that will be present in all Norwegian departments of cardiology. Post-MI patients can check the investigators web site (www.sefh.no) to determine whether they are eligible for the study. After consent and answering the baseline questionnaire, each participant will be randomized to either the intervention or control group. Control group: Standard surveillance after MI (no specific focus on sexual activity and functioning) Intervention group: Online sexual counselling including a short information film. In order to assess the generalizability of the results, we will compare the age, sex and MI treatment of the respondents with data on Norwegian MI-patients in general.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 11, 2022

Completed
25 days until next milestone

First Posted

Study publicly available on registry

April 5, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

November 7, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

November 16, 2022

Status Verified

March 1, 2022

Enrollment Period

12 months

First QC Date

March 11, 2022

Last Update Submit

November 11, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Does specific sexual counselling improve sexual functioning in post-MI?

    The investigators will measure sexual function by Brief Sexual Function Inventory (BSFI) for male participants and Female Sexual Function Index (FSFI) for female participants at 6 and 12 months after their MI.

    12 months

  • Changes in sexual activity and functioning after MI

    The investigators will measure sexual activity and function at baseline, and 6 and 12 months after MI. The investigators will measure sexual function by Brief Sexual Function Inventory (BSFI) for male participants and Female Sexual Function Index (FSFI) for female participants.

    12 months

  • Establish predictors of improved sexual functioning in post-MI patients

    In order to identify MI patients at risk of sexual dysfunction, the participants will answer questionnaires on quality of life (RAND-12), depression and anxiety (HADS), demographic data, comorbidity, medications and other factors that may have impact on sexual function.

    12 months

Study Arms (2)

Information film

ACTIVE COMPARATOR

Randomized to receive a short information film online.

Other: Information film

Standard care

NO INTERVENTION

No film, only questionnaire.

Interventions

* Sexual activity after MI does not increase risk of recurrence or death * Sexual activity is associated with improved outcome after MI * Resuming sexual activity as normal is recommended and completely safe

Information film

Eligibility Criteria

Age18 Years - 110 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women ≥18 years old
  • Acute MI during the last 6 weeks
  • Informed consent for participation

You may not qualify if:

  • Lack of ability to cooperate
  • Known alcohol- or drug-abuse, or use of narcotics
  • Pregnancy or breast-feeding
  • Serious comorbidity with a life expectancy \<12 months
  • Unstable or refractory angina
  • Uncontrolled hypertension
  • Congestive heart failure (NYHA class III/IV)
  • High-risk arrhythmias
  • Hypertrophic obstructive and other cardiomyopathies
  • Severe valvular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Www.Sefh.No

Arendal, Norway

RECRUITING

Related Links

MeSH Terms

Conditions

Sexual Dysfunctions, PsychologicalMyocardial Infarction

Condition Hierarchy (Ancestors)

Mental DisordersMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Officials

  • Frode Gallefoss

    Sorlandets hospital HF

    STUDY DIRECTOR

Central Study Contacts

Vibeke Salvesen, MD

CONTACT

Nora Johansen, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2022

First Posted

April 5, 2022

Study Start

November 7, 2022

Primary Completion

November 1, 2023

Study Completion

November 1, 2024

Last Updated

November 16, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations